Background: The objective was to study the annual cost of each of the four important brands of insulin glargine available in India and to study the comparative annual cost of all the four brands.Methods: Four most commonly prescribed brands of insulin glargine vials were selected for cost comparisons. The daily as well as annual cost of prescription of insulin glargine vials based on once daily use was worked out directly as well as in percentages and presented in the form of table and bar diagrams.Results: After careful analysis of the data it was found that the costliest brand, brand D is more than two times costlier than the cheapest brand, brand B and thus the brand preparation selection, can lead to huge difference in annual cost burde...
Background: People with type 2 diabetes typically require insulin treatment following failure on hyp...
Background: Economic aspects and patient-reported outcomes play an increasing role in the choice of ...
Background: Antiplatelet drugs need to be prescribed lifelong, for most of the selected patients, on...
Introduction: Poor drug compliance affects clinical outcome and increases healthcare costs in vario...
Background: Diabetes mellitus is a metabolic disorder requiring lifelong treatment. There are a larg...
Drug therapy (medicines) has a fundamental role in the healthcare system. An increase in the cost of...
Background: Diabetes, a chronic disorder and requires life-long treatment. Cost of drug treatment is...
Purpose: For years, traditional techniques have been used for diabetes treatment. There are two majo...
Background: The objective of this study was to analyze cost variations of oral antidiabetic drugs av...
Background: Diabetes mellitus in early age is on the alarming rise in India, requiring lifelong trea...
Background: The pivotal clinical trials programme used to evaluate insulin glargine for regulatory p...
Background: Hypolipidemic drugs need to be prescribed lifelong for most of the selected patients, on...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...
Aim: The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes o...
Background: Diabetes is one of the most common non-communicable disease worldwide, of which India ha...
Background: People with type 2 diabetes typically require insulin treatment following failure on hyp...
Background: Economic aspects and patient-reported outcomes play an increasing role in the choice of ...
Background: Antiplatelet drugs need to be prescribed lifelong, for most of the selected patients, on...
Introduction: Poor drug compliance affects clinical outcome and increases healthcare costs in vario...
Background: Diabetes mellitus is a metabolic disorder requiring lifelong treatment. There are a larg...
Drug therapy (medicines) has a fundamental role in the healthcare system. An increase in the cost of...
Background: Diabetes, a chronic disorder and requires life-long treatment. Cost of drug treatment is...
Purpose: For years, traditional techniques have been used for diabetes treatment. There are two majo...
Background: The objective of this study was to analyze cost variations of oral antidiabetic drugs av...
Background: Diabetes mellitus in early age is on the alarming rise in India, requiring lifelong trea...
Background: The pivotal clinical trials programme used to evaluate insulin glargine for regulatory p...
Background: Hypolipidemic drugs need to be prescribed lifelong for most of the selected patients, on...
Background: Two alternative basal analogue insulin treatments are available: insulin glargine (glarg...
Aim: The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes o...
Background: Diabetes is one of the most common non-communicable disease worldwide, of which India ha...
Background: People with type 2 diabetes typically require insulin treatment following failure on hyp...
Background: Economic aspects and patient-reported outcomes play an increasing role in the choice of ...
Background: Antiplatelet drugs need to be prescribed lifelong, for most of the selected patients, on...